446 related articles for article (PubMed ID: 17572410)
21. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids.
Lethaby A; Vollenhoven B; Sowter M
Cochrane Database Syst Rev; 2000; (2):CD000547. PubMed ID: 10796723
[TBL] [Abstract][Full Text] [Related]
22. Add-back therapy for long-term use in dysfunctional uterine bleeding and uterine fibroids.
Thomas EJ
Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():18-21. PubMed ID: 8916983
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of short-term administration of tibolone plus gonadotropin-releasing hormone analogue on the surgical outcome of laparoscopic myomectomy.
Palomba S; Pellicano M; Affinito P; Di Carlo C; Zullo F; Nappi C
Fertil Steril; 2001 Feb; 75(2):429-33. PubMed ID: 11172852
[TBL] [Abstract][Full Text] [Related]
24. [A comparative efficacy study of the preoperative use of GnRH agonists in women with uterine fibromyomas].
Nikolov A; Karag'ozov I
Akush Ginekol (Sofiia); 1999; 38(4):38-42. PubMed ID: 10726353
[TBL] [Abstract][Full Text] [Related]
25. Prolonged use of gonadotropin-releasing hormone agonist and tibolone as add-back therapy for the treatment of endometrial hyperplasia.
Agorastos T; Vaitsi V; Paschopoulos M; Vakiani A; Zournatzi-Koiou V; Saravelos H; Kostopoulou E; Constantinidis T; Dinas K; Vavilis D; Lolis D; Bontis J
Maturitas; 2004 Jun; 48(2):125-32. PubMed ID: 15172086
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and safety investigation of Kuntai capsule for the add-back therapy of gonadotropin releasing hormone agonist administration to endometriosis patients: a randomized, double-blind, blank- and tibolone-controlled study.
Chen JM; Gao HY; Ding Y; Yuan X; Wang Q; Li Q; Jiang GH
Chin Med J (Engl); 2015 Feb; 128(4):427-32. PubMed ID: 25673440
[TBL] [Abstract][Full Text] [Related]
27. Administration of goserelin acetate after uterine artery embolization does not change the reduction rate and volume of uterine myomas.
Vilos GA; Vilos AG; Abu-Rafea B; Pron G; Kozak R; Garvin G
Fertil Steril; 2006 May; 85(5):1478-83. PubMed ID: 16579996
[TBL] [Abstract][Full Text] [Related]
28. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies.
Gallagher JC; Baylink DJ; Freeman R; McClung M
J Clin Endocrinol Metab; 2001 Oct; 86(10):4717-26. PubMed ID: 11600531
[TBL] [Abstract][Full Text] [Related]
29. [Effect of GnRH analogues pre-treatment on myomectomy outcomes in reproductive age women].
Hudecek R; Ivanová Z; Smerdová M; Pánková S; Krajcovicová R
Ceska Gynekol; 2012 Apr; 77(2):109-17. PubMed ID: 22702067
[TBL] [Abstract][Full Text] [Related]
30. The prevention of bone loss in young women treated with GnRH analogues with "add-back" estrogen therapy.
Leather AT; Studd JW; Watson NR; Holland EF
Obstet Gynecol; 1993 Jan; 81(1):104-7. PubMed ID: 8416441
[TBL] [Abstract][Full Text] [Related]
31. GnRH agonists before surgery for uterine leiomyomas. A review.
Crosignani PG; Vercellini P; Meschìa M; Oldani S; Bramante T
J Reprod Med; 1996 Jun; 41(6):415-21. PubMed ID: 8799917
[TBL] [Abstract][Full Text] [Related]
32. A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata.
Schlaff WD; Zerhouni EA; Huth JA; Chen J; Damewood MD; Rock JA
Obstet Gynecol; 1989 Dec; 74(6):856-62. PubMed ID: 2511532
[TBL] [Abstract][Full Text] [Related]
33. Effect of tibolone on breast cancer cell proliferation in postmenopausal ER+ patients: results from STEM trial.
Kubista E; Planellas Gomez JV; Dowsett M; Foidart JM; Pohlodek K; Serreyn R; Nechushkin M; Manikhas AG; Semiglazov VF; Hageluken CC; Singer CF
Clin Cancer Res; 2007 Jul; 13(14):4185-90. PubMed ID: 17634547
[TBL] [Abstract][Full Text] [Related]
34. Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The Leuprolide Study Group.
Friedman AJ; Hoffman DI; Comite F; Browneller RW; Miller JD
Obstet Gynecol; 1991 May; 77(5):720-5. PubMed ID: 1901638
[TBL] [Abstract][Full Text] [Related]
35. Tibolone and osteoporosis.
Lazovic G; Radivojevic U; Milosevic V; Lazovic A; Jeremic K; Glisic A
Arch Gynecol Obstet; 2007 Dec; 276(6):577-81. PubMed ID: 17605023
[TBL] [Abstract][Full Text] [Related]
36. Tibolone: prevention of bone loss in late postmenopausal women.
Bjarnason NH; Bjarnason K; Haarbo J; Rosenquist C; Christiansen C
J Clin Endocrinol Metab; 1996 Jul; 81(7):2419-22. PubMed ID: 8675554
[TBL] [Abstract][Full Text] [Related]
37. Should add-back therapy for endometriosis be deferred for optimal results?
Kiesel L; Schweppe KW; Sillem M; Siebzehnrübl E
Br J Obstet Gynaecol; 1996 Oct; 103 Suppl 14():15-7. PubMed ID: 8916982
[TBL] [Abstract][Full Text] [Related]
38. Gonadotropin-releasing hormone agonist pretreatment did not decrease postoperative adhesion formation after abdominal myomectomy in a randomized control trial.
Coddington CC; Grow DR; Ahmed MS; Toner JP; Cook E; Diamond MP
Fertil Steril; 2009 May; 91(5):1909-13. PubMed ID: 18439584
[TBL] [Abstract][Full Text] [Related]
39. Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis.
Taskin O; Yalcinoglu AI; Kucuk S; Uryan I; Buhur A; Burak F
Fertil Steril; 1997 Jan; 67(1):40-5. PubMed ID: 8986681
[TBL] [Abstract][Full Text] [Related]
40. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata.
Chwalisz K; Larsen L; Mattia-Goldberg C; Edmonds A; Elger W; Winkel CA
Fertil Steril; 2007 Jun; 87(6):1399-412. PubMed ID: 17307170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
